S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Alnylam PharmaceuticalsRoyalty PharmaUCBCatalentCureVac
Price Information
Current Price$143.39$42.54$97.35$104.55$82.69
52 Week RangeHoldHoldBuyBuyHold
Overall Score1.
Analysis Score3.
Community Score3.
Dividend Score0.
Ownership Score1.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyHold
Consensus Price Target$163.42$51.88N/A$125.13$58.33
% Upside from Price Target13.97% upside21.94% upsideN/A19.68% upside-29.46% downside
Trade Information
Market Cap$16.78 billion$16.51 billion$18.94 billion$17.80 billion$15.46 billion
Average Volume793,1682,668,1112401,019,647837,393
Sales & Book Value
Annual Revenue$219.75 millionN/A$5.50 billion$3.09 billionN/A
Price / Sales76.35N/A3.445.75N/A
CashflowN/AN/A$5.10 per share$3.39 per shareN/A
Price / CashN/AN/A19.0930.82N/A
Book Value$12.90 per shareN/A$40.36 per share$18.71 per shareN/A
Price / Book11.12N/A2.415.59N/A
Net Income$-886,120,000.00N/A$887.04 million$173 millionN/A
Trailing P/E RatioN/A0.0016.7366.590.00
Forward P/E RatioN/A15.8114.1537.74N/A
P/E GrowthN/A1.94N/A2.68N/A
Net Margins-222.19%N/AN/A9.25%N/A
Return on Equity (ROE)-65.96%N/AN/A14.20%N/A
Return on Assets (ROA)-31.38%N/AN/A4.83%N/A
Annual PayoutN/A$0.68N/AN/AN/A
Dividend YieldN/A1.60%N/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/A1 YearsN/AN/AN/A
Debt-to-Equity RatioN/A0.59%N/A0.97%N/A
Current Ratio5.32%10.31%N/A2.56%N/A
Quick Ratio5.18%10.31%N/A2.14%N/A
Ownership Information
Institutional Ownership Percentage92.35%40.85%N/A97.84%4.32%
Insider Ownership Percentage3.50%2.50%N/A1.00%N/A
Shares Outstanding117.00 million388.13 million194.51 million170.23 million186.91 million
Next Earnings Date5/5/2021 (Estimated)5/19/2021 (Estimated)5/27/2021 (Estimated)5/4/2021 (Estimated)N/A
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.